摘要
目的探讨KAI1/CD82在乳腺癌进展中的作用及其在预后判断中的价值。方法采用免疫组化方法对60例有临床和随访资料的乳腺癌组织进行KAI1/CD82蛋白表达的研究。以15例良性乳腺瘤,15例正常乳腺组织作对照,分析与临床病理指标的关系。结果在乳腺癌原发灶中KAI1/CD82阳性表达41．66%,较正常乳腺组织(80%)、良性乳腺瘤(73．33%)明显减少(P＜0．01、P＜0．05)。KAI1/CD82在有淋巴结转移、周围组织侵润、远处脏器转移肿瘤中表达显著降低(P＜0．01、P＜0．05、P＜0．05),生存5年以上者的KAI1/CD82蛋白阳性表达率59．38%,明显高于生存时间不超过5年者21．43%(P＜0．01)。患者的术后复发情况与KAI1/CD82表达无关。结论KAI1/CD82的异常表达可能参与了乳腺癌的恶性进展。检测KAI1/CD82的表达对判断肿瘤的侵袭、转移及乳腺癌患者预后有一定的参考价值。
Objective To study relationship between expression of KAI1/CD82 and metastasis, prognosis in breast carter. Methods Expression of KAI1/CD82 protein was examined by immunohistochemistry techique in 60 cases of malignant breast tissues, 15 cases of benign breast tissues and 15 cases of normal breast tissues. The correlation between the expression of KAI1/CD82 protein and clinical factors was analyzed.Results The positive expression rates of KAI1/CD82 protein in malignant breast tissues was 41.66% ,and was significantly lower than that of benign breast tissues and normal breast tissues. Low-expression of KAI1/CD82 protein was associated with lymph node metastasis（ P 〈 0.01 ） and invasion（ P 〈 0.05）. Patients with low-expression of KAI1/CD82 protein had poor prognosis. Expression of KAI1/CD82 was not related to recurrenee. The abnormal expression of KAI1/CD82 may play an important role in malignant progression of breast cancer. KAI1/CD82 is considered as a marker to predict metastasis and prognosis of patients.
出处
《实用肿瘤学杂志》
CAS
2007年第3期234-235,237,共3页
Practical Oncology Journal
基金
黑龙江省教育厅科学技术研究项目(编号:10541144)
